Introduction
Epidemiological studies have shown a higher incidence of cardiovascular morbidity and mortality in persons with epilepsy compared to the general population [1, 2] . This association was noted to be more profound in individuals aged below 65 years [2] .
Alterations of the metabolic components of the body can lead to adverse cardiovascular and cerebrovascular events. Metabolic syndrome (MetS) was defined by Reaven in 1988 as clustering of multiple interrelated risk factors with attendant two fold increased risk of cardiovascular disease [3] . Drugs used to treat epilepsy are known to alter the metabolic milieu of the body, especially the lipid levels, acute phase reactants and coagulation profile [4, 5] . However, very few studies have explored the relationship of epilepsy and its treatment with MetS. The objective of this study was to examine the prevalence of MetS and cardiovascular risk factors in young adults with epilepsy from a tertiary care neurology centre and study their association with antiepileptic drug use.
Methods
This observational cross-sectional study was carried out between January 2012 and June 2013 in the weekly Epilepsy outpatient clinic in Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, India. On each day of the clinic, we recruited the first five patients who fulfilled the selection criteria and consented to participate in this study.
Persons aged 20-49 years with active epilepsy and using antiepileptic drugs for the past three years or more were eligible for inclusion. Patients with diabetes mellitus, systemic hypertension or dyslipidemia pre-dating the onset of epilepsy, patients on drugs (such as steroids, beta blockers and hormonal contraceptives) known to alter the lipid profile, pregnant women and women in the first 6 months postpartum period were excluded.
The demographic data, characteristics of the epilepsy, presence of metabolic risk factors and cardiovascular disease were recorded on a standard proforma. Fasting blood glucose and lipid profile were evaluated from venous blood drawn after 8 h of fasting.
Purpose: Persons with epilepsy have higher cardiovascular mortality and morbidity compared to general population and alteration of their biochemical milieu is one of the proposed mechanisms. We aimed to study the prevalence of metabolic syndrome and cardiovascular risk factors in young adults with epilepsy and the association with antiepileptic drug use. Method: An observational study was conducted in persons with epilepsy aged 20-49 years using antiepileptic drugs regularly for the previous three years. The subjects were examined and their blood samples were collected for fasting blood glucose and lipid profile. Results: Over 18 months, 183 patients (120 males; 63 females) were recruited (mean age 32.5 AE 8.9 years). Metabolic syndrome (MetS) by ATP III criteria was present in 54 (29.5%) subjects. People with MetS in our group had higher frequency of abdominal obesity (50.0%) and hypertriglyceridemia (55.5%) than diabetes/impaired fasting glucose (27.8%). Older age (p = 0.005) and use of valproate (p = 0.012) were associated with significant risk of MetS. Conclusion: Clinicians need to be vigilant regarding the risk of MetS while initiating treatment and following up persons with epilepsy.
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A cardiologist carried out the cardiac evaluation and electrocardiography for all subjects. We used the National Cholesterol Education Program's Adult Treatment Panel III (ATP III) [6] criteria for MetS modified for Asian population [7] which defines MetS as presence of at least three of five features: central (abdominal) obesity (waist circumference >90 cm in males and >80 cm in females), raised triglycerides (!150 mg/dl or specific treatment for this), reduced HDL cholesterol (<40 mg/dl in males, <50 mg/dl in females or specific treatment for this), raised blood pressure (systolic BP ! 130 mm Hg or diastolic BP ! 85 mm Hg or treatment of previously diagnosed hypertension) and raised fasting plasma glucose (FPG ! 110 mg/dl or treatment of previously diagnosed type 2 diabetes).
Study had the approval of the Institutional Ethics committee and informed consent was obtained from all participants.
Statistical analysis was done with SPSS software for Windows version 21. Means of numeric variables were compared between groups by Student's t-test. Proportions were compared by Chisquare test or Fisher's exact test. p values of less than 0.05 were taken for statistical significance. We compared the results from our subjects with the general population characteristics from a previous study in one of the Indian states [8] using Student's t-test (to compare the means) and Chi-square test (to compare the proportions).
Results
We recruited 183 patients fulfilling the inclusion and exclusion criteria from 4312 patients who attended the Epilepsy Clinic during the period of the recruitment. There were 120 (65.9%) males and 63 (34.1%) females with mean age of 32.5 (AE8.9) years (range 20-49 years). The demographic and clinical profiles of the subjects are given in Table 1 .
All the patients were on antiepileptic drugs at the time of recruitment. More than half of the subjects (51.9%) were on monotherapy and the rest were on two antiepileptic drugs (37.16%) or more than two antiepileptic drugs (10.9%). Carbamazepine, sodium valproate, phenytoin, clobazam and phenobarbitone were used as monotherapy or in combination in 178 (97.27%) of the 183 patients ( Table 1 MetS (by ATP III criteria) was present in 54 (29.5%) patients. In the total cohort, abdominal obesity was detected in 81 patients (44.3%). Eight (4.37%) of the enrolled patients were diagnosed to have diabetes mellitus after the onset of epilepsy and another 10 had impaired fasting blood glucose. 105 (55.56%) patients had high systolic and/or diastolic blood pressure at examination or were on treatment for systemic hypertension. 93 (50.8%) patients had abnormal fasting lipid levels or were on treatment for the same. The distribution of the components of MetS is shown in Table 1 .
Five of the patients were smokers and none of them had MetS. Only one patient exercised regularly. Family history of coronary artery disease or stroke was present for 4 patients. These factors were not significantly different between the patients with and without MetS. Two patients in the study cohort had coronary heart disease proven by coronary angiography. 
Discussion
This study looked at the prevalence of MetS and cardiovascular risk factors specifically in a younger age group where the population risk is relatively low. A minimum of three years treatment with antiepileptic drugs ensured that the drug effect is captured well in this study.
The key finding in the study was that nearly one-third of the adults below 50 years with epilepsy have MetS. Gupta et al. had reported the prevalence of MetS in the general population of similar age in the northern state of Rajasthan in India to be 21.9% [8] . The prevalence of MetS in this study (29.5%) was higher than that from general population but the difference did not reach statistical significance (p = 0.066). However, males in our cohort had significantly higher frequency of MetS compared to the males in general population (32.5% vs. 17.41%, p = 0.001). This difference was not due to the age composition or difference in drug use between males and females in our group (Table 2) .
We observed a significant association between use of valproate and the prevalence of MetS in persons with epilepsy. There are limitations in comparing our data with the previously published studies where the metabolic effects of valproate were studied in specific and restricted groups. A meta-analysis of bipolar disorder patients on valproate and other drugs showed the prevalence of MetS to range widely from 16.7 to 49% [9] . Obese patients on valproate for epilepsy had a non-significant increased prevalence of metabolic syndrome compared to matched obese patients not on medication in a study conducted in China [10] . However the former group had a significantly higher insulin resistance. The MetS associated with valproate exposure in our sample had more of abdominal obesity and hypertriglyceridemia than diabetes. Although valproate therapy is linked to weight gain [11, 12] , the biochemical mechanisms leading to it remain speculative. The putative mechanisms include valproate induced direct stimulation of the hypothalamus via GABA pathway and alterations of adipokine gene expression in brain and pituitary and adipokine release from adipose tissue [12] . Valproate may alter the metabolism of insulin in the liver culminating in insulin resistance [13] irrespective of body weight. It appears valproate promotes MetS by weight gain and by its own intrinsic effects on the physiological pathways. In addition, sedentary life, lack of profitable employment and unhealthy lifestyle may influence MetS in persons with epilepsy. Our study had certain limitations. As the study was conducted in a tertiary care centre, the group of epilepsy patients selected may reflect more resistant cases of epilepsy than those in general population. Also, a comparative control group from the same geographic area would have been ideal. This study shows that nearly 30% of young adults with epilepsy have MetS with exposure to valproate associated with increased risk. The MetS in epilepsy is characterized by higher frequency of abdominal obesity and hypertriglyceridemia than diabetes. While choosing the antiepileptic medications, clinicians should be conscious of this risk. Patients on medications prone to these adverse effects should be counselled and monitored for weight gain, MetS and attendant cardiovascular risk. The direct impact of these observations on the cardiovascular morbidity in these patients can only be assessed by further longitudinal studies.
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